Clinical Significance of ErbB Receptor Family in Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-Analysis

Table 5

The update results of published clinical trials targeting EGFR signaling in urothelial carcinoma patients.

Study agents	Pts no.	ORR (%)	Recommendation
EGFR signaling
Cetuximab + paclitaxel versus cetuximab	39	28.5 versus 18	The combination merits further evaluation [38]
Geftinib + Gemcitabine, cisplatin	58	42.6%	The combination of cisplatin, gemcitabine, and gefitinib is well tolerated, and the addition of gefitinib does not appear to improve response rate or survival [39, 40]
Geftinib	31	6.5	Geftinib (ZD1839) is ineffective as a second-line agent for urothelial carcinoma [41]
EGFR and ErbB2 signaling
Lapatinib	59	ORR (1.7%) and; SD (31%)	A negative result, but clinical benefit (ORR and SD) is correlated with EGFR overexpression (𝑃=0.029), and, to some extent, HER-2 overexpression [42]
EGFR, VEGFR, and RET signaling
Vandetanib plus docetaxel versus placebo plus docetaxel	142	ORR, 7 versus 11 (𝑃=0.56); PFS,; 2.6 m versus 1.6 m (𝑃=0.939); OS, 5.9 m versus 7.0 m (𝑃=0.347)	The addition of vandetanib to docetaxel did not result in a significant improvement in PFS, ORR, or OS [43]

ORR: objective response rate; SD: stable disease, PFS: progression-free survival; OS: overall survival; VEGFR: vascular endothelial growth factor receptor; RET: rearranged during transfection.